|
Positron Emission Tomography in Determining Stage of Esophageal Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Positron Emission Tomography in Determining Stage of Esophageal Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Positron Emission Tomography in Determining Stage of Esophageal Cancer Clinical research trials and Positron Emission Tomography in Determining Stage of Esophageal Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Positron Emission Tomography in Determining Stage of Esophageal Cancer. Positron Emission Tomography in Determining Stage of Esophageal Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Positron Emission Tomography in Determining Stage of Esophageal Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Positron Emission Tomography in Determining Stage of Esophageal Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Positron Emission Tomography in Determining Stage of Esophageal Cancer  Positron Emission Tomography in Determining Stage of Esophageal Cancer
Positron Emission Tomography in Determining Stage of Esophageal Cancer
For Condition: stage 2 esophageal cancer,Adenocarcinoma of the Esophagus,stage 3 esophageal cancer,stage 4 esophageal cancer,squamous cell carcinoma of the esophagus,stage 1 esophageal cancer
Status: Recruiting
Sponsor(s): American College of Surgeons , National Cancer Institute (NCI)
Synopsis: RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: Diagnostic trial of fludeoxyglucose F 18 positron emission tomography to determine tumor stage of esophageal cancer.
Details: OBJECTIVES: - Determine the efficacy of fludeoxyglucose F 18 positron emission tomography imaging in detecting lesions that would preclude esophagectomy in patients with carcinoma of the thoracic esophagus or gastroesophageal junction. OUTLINE: This is a multicenter study. Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation. Patients are followed within 6 months after surgery. PROJECTED ACCRUAL: A total of 120-235 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven adenocarcinoma or squamous cell carcinoma of the thoracic esophagus (at least 20 cm from incisors) or gastroesophageal junction - Stage T1-3, N0-1, M0-1a - Amenable to curative surgery - No proximal esophageal cancer (less than 20 cm from incisors) potentially requiring pharyngolaryngoesophagectomy - Regional lymph node involvement allowed - No unresectable locoregional invasion - No distant metastatic disease including any or all of the following: - Positive cytology of the pleura, pericardium, or peritoneum - Metastasis to the brain, bone, lung, liver, or adrenals - Involvement of the tracheobronchial tree (positive bronchoscopic biopsy or overt esophagorespiratory fistula) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - No uncontrolled diabetes mellitus (fasting blood glucose greater than 200mg/dL) within 12 hours prior to PET scan (no diabetic medications within 4 hours prior to checking blood glucose level) - Able to fast for at least 4 hours - Able to tolerate PET imaging - Not claustrophobic - Able to lie supine for 1.5 hours - Not pregnant - Negative pregnancy test - No other malignancy within the past 5 years except completely resected cervical cancer or nonmelanomatous skin cancer and prior malignancy at low risk of recurrence - Medically fit for staging procedures or esophagectomy PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Neoadjuvant chemotherapy or chemoradiotherapy allowed if administered after fludeoxyglucose F 18 positron emission tomography (PET) imaging Endocrine therapy: - Not specified Radiotherapy: - See Chemotherapy - Neoadjuvant radiotherapy allowed if administered after fludeoxyglucose F 18 PET imaging Surgery: - See Disease Characteristics Other: - No prior fludeoxyglucose F 18 PET imaging - Concurrent enrollment in other clinical trials allowed except those involving fludeoxyglucose F 18 PET imaging
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BryanMeyers, Study Chair, Barnes-Jewish Hospital
Greater Baltimore Medical Center and Cancer Center *Recruiting*
Baltimore, Maryland, 23298-0068
United States
Recruiting Neri Cohen 443-849-3470
William Beaumont Hospital - Royal Oak *Recruiting*
Royal Oak, Michigan, 48073
United States
Recruiting Gary Chmielewski 248-551-0669
Mobile Infirmary Medical Center *Recruiting*
Mobile, Alabama, 36640-0460
United States
Recruiting Gaylord Walker 251-433-5557
Hollings Cancer Center at Medical University of South Carolina *Recruiting*
Charleston, South Carolina, 29425
United States
Recruiting Carolyn Reed 843-792-3362
Providence Cancer Center at Providence Portland Medical Center *Recruiting*
Portland, Oregon, 97213-2967
United States
Recruiting John Handy 503-215-2300
LDS Hospital *Recruiting*
Salt Lake City, Utah, 84143
United States
Recruiting Michael Collins 801-408-2260
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center *Recruiting*
Nashville, Tennessee, 37232-6838
United States
Recruiting Matthew Ninan 615-322-0064
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting David Jablons 415-885-3882
University Hospital at State University of New York - Upstate Medical University *Recruiting*
Syracuse, New York, 13210
United States
Recruiting Leslie Kohman 315-464-6321
Allegheny General Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15212-4772
United States
Recruiting Robert Keenan 412-359-6202
Akron General Medical Center *Recruiting*
Akron, Ohio, 44302
United States
Recruiting Daniel Guyton 330-344-6234
University of Alabama at Birmingham Comprehensive Cancer Center *Recruiting*
Birmingham, Alabama, 35294-3300
United States
Recruiting Marshall Urist 205-934-3028
Morton Plant Hospital *Recruiting*
Clearwater, Florida, 33756
United States
Recruiting Peter Blumencranz 727-446-5681
Westmoreland Regional Hospital *Recruiting*
Greensburg, Pennsylvania, 15601-2282
United States
Recruiting Robert Keenan 412-359-6202
Tri-Health Good Samaritan Hospital *Recruiting*
Cincinnati, Ohio, 90027
United States
Recruiting Joseph Guenther 513-961-4335
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus *Recruiting*
Nashville, Tennessee, 37232-0001
United States
Recruiting Matthew Ninan 615-322-0064
Massey Cancer Center at Virginia Commonwealth University *Recruiting*
Richmond, Virginia, 23298-0037
United States
Recruiting Abelardo DeAnda 804-828-2775
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Valerie Rusch 212-639-5873
Western Pennsylvania Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15224
United States
Recruiting Robert Keenan 412-359-6202
University of Tennessee, Memphis *Recruiting*
Memphis, Tennessee, 38163
United States
Recruiting Derrick Beech 901-448-1542
St. Clair Memorial Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15243-1899
United States
Recruiting Robert Keenan 412-359-6202
Bethesda North Hospital *Recruiting*
Cincinnati, Ohio, 45242
United States
Recruiting Joseph Guenther 513-961-4335
Marlene and Stewart Greenebaum Cancer Center, University of Maryland *Recruiting*
Baltimore, Maryland, 21201
United States
Recruiting Mark Krasna 410-328-6366
University of South Alabama Medical Center *Recruiting*
Mobile, Alabama, 36617-2293
United States
Recruiting Joseph LoCicero 251-471-7993
Arthur G. James Cancer Hospital - Ohio State University *Recruiting*
Columbus, Ohio, 43210-1240
United States
Recruiting William Burak 614-293-8550
University of Colorado Cancer Center at University of Colorado Health Sciences Center *Recruiting*
Aurora, Colorado, 80010
United States
Recruiting Christina Finlayson 303-315-8671
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center *Recruiting*
Orange, California, 92868
United States
Recruiting Jeffrey Milliken 714-456-3634
Indiana University Cancer Center *Recruiting*
Indianapolis, Indiana, 46202-5289
United States
Recruiting Kenneth Kesler 317-274-2394
Jonsson Comprehensive Cancer Center, UCLA *Recruiting*
Los Angeles, California, 90095-1781
United States
Recruiting Robert Cameron 310-794-7333
Barnes-Jewish Hospital *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Bryan Meyers 314-362-8598
Baylor University Medical Center *Recruiting*
Dallas, Texas, 75246
United States
Recruiting Jeffrey Stephens 214-826-6276
Stanford Cancer Center at Stanford University Medical Center *Recruiting*
Stanford, California, 94305-5407
United States
Recruiting Richard Whyte 650-723-6649
Duke Comprehensive Cancer Center *Recruiting*
Durham, North Carolina, 27710
United States
Recruiting Douglas Tyler 919-684-6858
Massachusetts General Hospital Cancer Center *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting Kenneth Tanabe 617-724-3868
Jameson Memorial Hospital *Recruiting*
New Castle, Pennsylvania, 16105
United States
Recruiting Robert Keenan 412-359-6202
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus *Recruiting*
Seattle, Washington, 98104
United States
Recruiting Ralph Aye 206-682-4790
Additional Information:
Study ID Numbers: CDR0000067526; ACOSOG-Z0060
Study Start Date:
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004867
Other Stage 4 Esophageal Cancer Studies:
1. Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus
2. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
3. Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
4. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
5. Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Related Studies:
Other stage 4 esophageal cancer Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials
Positron Emission Tomography in Determining Stage of Esophageal Cancer
|
|
|
|
|
|
|
|
